Literature DB >> 32024694

A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).

Zachary Hartman1, Werner J Geldenhuys2, Yehenew M Agazie3,4.   

Abstract

The Src homology phosphatase 2 (SHP2) is a cytoplasmic enzyme that mediates signaling induced by multiple receptor tyrosine kinases, including signaling by the epidermal growth factor receptor (EGFR) family (EGFR1-4 or the human homologs HER1-4). In EGFR (HER1) and EGFR2 (HER2) signaling, SHP2 increases the half-life of activated Ras by blocking recruitment of Ras GTPase-activating protein (RasGAP) to the plasma membrane through dephosphorylation of docking sites on the receptors. However, it is unclear how SHP2 selectively recognizes RasGAP-binding sites on EGFR and HER2. In this report, we show that SHP2-targeted pTyr residues exist in a specific amino acid context that allows selective binding. More specifically, we show that acidic residues N-terminal to the substrate pTyr in EGFR and HER2 mediate specific binding by the SHP2 active site, leading to blockade of RasGAP binding and optimal signaling by the two receptors. Molecular modeling studies revealed that a peptide derived from the region of pTyr992-EGFR packs well and makes stronger interactions with the SHP2 active site than with the SHP1 active site, suggesting a built-in mechanism that enables selective substrate recognition by SHP2. A phosphorylated form of this peptide inhibits SHP2 activity in vitro and EGFR and HER2 signaling in cells, suggesting inhibition of SHP2 protein tyrosine phosphatase activity by this peptide. Although we do not expect this peptide to be a strong inhibitor by itself, we foresee that the insights into SHP2 selectivity described here will be useful in future development of active-site small molecule-based inhibitors.
© 2020 Hartman et al.

Entities:  

Keywords:  EGF signaling; EGFR; HER2; Peptide inhibitor; SHP2; breast cancer; inhibitor; phosphatase; receptor tyrosine kinase; signal transduction

Year:  2020        PMID: 32024694      PMCID: PMC7076199          DOI: 10.1074/jbc.RA119.011422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Crystal structure of the tyrosine phosphatase SHP-2.

Authors:  P Hof; S Pluskey; S Dhe-Paganon; M J Eck; S E Shoelson
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

2.  Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction.

Authors:  A M O'Reilly; B G Neel
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

3.  Regulation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2.

Authors:  Jiao-Hui Wu; Robi Goswami; Xinjiang Cai; Sabrina T Exum; Xuewei Huang; Lisheng Zhang; Leigh Brian; Richard T Premont; Karsten Peppel; Neil J Freedman
Journal:  J Biol Chem       Date:  2006-10-03       Impact factor: 5.157

4.  Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates.

Authors:  Yehenew M Agazie; Michael J Hayman
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

Review 5.  Protein tyrosine phosphatase: enzymatic assays.

Authors:  Jacqueline Montalibet; Kathryn I Skorey; Brian P Kennedy
Journal:  Methods       Date:  2005-01       Impact factor: 3.608

6.  Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation.

Authors:  Ju Li; Sarah A Reed; Sally E Johnson
Journal:  Exp Cell Res       Date:  2009-04-23       Impact factor: 3.905

7.  Direct binding of Grb2 SH3 domain to FGFR2 regulates SHP2 function.

Authors:  Zamal Ahmed; Roger George; Chi-Chuan Lin; Kin Man Suen; James A Levitt; Klaus Suhling; John E Ladbury
Journal:  Cell Signal       Date:  2009-09-06       Impact factor: 4.315

8.  The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.

Authors:  Zachary R Hartman; Michael D Schaller; Yehenew M Agazie
Journal:  Mol Cancer Res       Date:  2013-03-19       Impact factor: 5.852

9.  Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.

Authors:  Hua Zhao; Yehenew M Agazie
Journal:  BMC Cancer       Date:  2015-03-08       Impact factor: 4.430

Review 10.  Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents.

Authors:  Antonella Borrelli; Anna Lucia Tornesello; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Molecules       Date:  2018-01-31       Impact factor: 4.411

View more
  4 in total

1.  Significance of Polar Charged Amino Acids in Compound Mutations in EGFR-mutated Patients Treated With First-line Afatinib.

Authors:  Hiroaki Satoh; Yuika Sasatani; Kunihiko Miyazaki; Yoshiharu Sato; Nobuyuki Hizawa
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Dissecting protein tyrosine phosphatase signaling by engineered chemogenetic control of its activity.

Authors:  Jordan Fauser; Vincent Huyot; Jacob Matsche; Barbara N Szynal; Yuri Alexeev; Pradeep Kota; Andrei V Karginov
Journal:  J Cell Biol       Date:  2022-07-13       Impact factor: 8.077

3.  Structural insights into the pSer/pThr dependent regulation of the SHP2 tyrosine phosphatase in insulin and CD28 signaling.

Authors:  András Zeke; Tamás Takács; Péter Sok; Krisztina Németh; Klára Kirsch; Péter Egri; Ádám Levente Póti; Isabel Bento; Gábor E Tusnády; Attila Reményi
Journal:  Nat Commun       Date:  2022-09-16       Impact factor: 17.694

4.  Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.

Authors:  Zachary Hartman; Werner J Geldenhuys; Yehenew M Agazie
Journal:  ACS Omega       Date:  2020-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.